A clinical-stage global biopharmaceutical company developing innovative immunotherapies that target G Protein-Coupled Receptors (GPCRs) to improve cancer treatment. The focus includes proprietary programs and a pipeline of GPCR targets identified through a cross-validation drug discovery platform.